🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,57 USD

Máx. histórico

178,74

2144 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,17%

Rango 52 semanas

14,68 – 24,68

Variación hoy

-7,48%

Cierre anterior

18,99

Rango de hoy

17,44 – 18,92

Volumen hoy

1.859.162

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 10 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
28/10/2021 77,53 79,57 76,97 79,25 +2,55% 3,35% 853.900
27/10/2021 77,99 79,13 76,65 77,28 -0,91% 3,18% 744.700
26/10/2021 79,70 80,00 77,80 77,99 -2,13% 2,76% 746.200
25/10/2021 80,41 80,85 79,32 79,69 -0,69% 1,90% 705.000
22/10/2021 80,66 81,51 79,05 80,24 -0,84% 3,05% 713.500
21/10/2021 79,88 81,57 79,88 80,92 +1,30% 2,12% 872.700
20/10/2021 80,44 80,99 78,11 79,88 -0,70% 3,58% 802.700
19/10/2021 81,09 82,59 80,05 80,44 -0,96% 3,13% 974.200
18/10/2021 84,10 84,81 79,88 81,22 -3,53% 5,86% 2.155.200
15/10/2021 83,16 85,78 82,50 84,19 +1,43% 3,94% 1.901.400
14/10/2021 83,50 85,75 82,27 83,00 -0,26% 4,17% 3.794.300
13/10/2021 88,90 89,71 83,01 83,22 -12,46% 7,54% 2.699.700
12/10/2021 93,23 97,00 93,23 95,07 +4,14% 4,04% 1.148.500
11/10/2021 96,17 97,95 90,51 91,29 -8,18% 7,74% 2.112.000
08/10/2021 94,97 101,24 94,50 99,42 +4,65% 7,10% 1.357.500
07/10/2021 97,25 99,59 94,86 95,00 -2,34% 4,86% 873.400
06/10/2021 94,52 98,79 93,74 97,28 +2,21% 5,34% 863.500
05/10/2021 94,85 96,90 93,49 95,18 +0,55% 3,60% 1.326.700
04/10/2021 96,29 98,11 93,42 94,66 -1,45% 4,87% 897.400
01/10/2021 91,72 96,20 90,91 96,05 +3,86% 5,77% 840.500
30/09/2021 88,98 93,50 88,91 92,48 +4,18% 5,16% 1.195.200
29/09/2021 92,78 92,93 88,68 88,77 -3,52% 4,58% 691.600
28/09/2021 90,56 93,01 89,15 92,01 +1,02% 4,26% 794.200
27/09/2021 90,43 91,55 89,70 91,08 +0,56% 2,05% 950.200
24/09/2021 90,10 91,80 90,01 90,57 +0,03% 1,99% 968.300
23/09/2021 87,14 90,69 86,99 90,54 +3,51% 4,25% 1.135.100
22/09/2021 87,40 88,48 86,05 87,47 -0,17% 2,78% 635.600
21/09/2021 86,09 88,88 85,90 87,62 +2,28% 3,46% 812.900
20/09/2021 85,00 87,34 84,37 85,67 -0,82% 3,49% 696.900
17/09/2021 85,43 86,77 83,38 86,38 +0,88% 3,97% 1.930.000